Migraine Management: Current Pharmacological and Non-pharmacological Options is a comprehensive guide to established, recent, and ongoing pharmaceuticals and device development projects. The book provides detailed information on the historical developments of migraine pain management, druggable targets, drugs action mechanisms, drugs for acute treatment and preventive care of patients, administration routes, and alternative treatments. This is the ideal reference for academic researchers interested in anti-migraine pharmacology. It will also be a perfect reference for physicians and care professionals involved in the well-being of migraine patients.
1. Chapter 1 Introduction - p. 3 2. Chapter 2 Neuroanatomy and neurophysiology of migraine - p. 21 3. Chapter 3 Historical overview of migraine product development - p. 35 4. Chapter 4 Comorbidities in migraine - p. 61 5. Chapter 5 Not all migraine attacks are the same - p. 81 6. Chapter 6 Challenges and controversies; pharmacokinetics, linguistics, semantics and statistics - p. 93 7. Chapter 7 Calcitonin gene-related peptide (CGRP) and its role in migraine - p. 121 8. Chapter 8 PACAP - p. 139 9. Chapter 9 Src family kinases (SFKs) in migraine - p. 153 10. Chapter 10 Delta opioid receptor system - p. 167 11. Chapter 11 Piezo channels in peripheral trigeminal nociception - p. 177 12. Chapter 12 TRP channel antagonists - p. 189 13. Chapter 13 Simple analgesics and combination oral products - p. 211 14. Chapter 14 Medical cannabis and cannabinoids - p. 225 15. Chapter 15 Ergots - p. 243 16. Chapter 16 Triptans - p. 257 17. Chapter 17 Beta blocker (timolol) eye drops - p. 279 18. Chapter 18 Lasmiditan (and the ditan class) - p. 289 19. Chapter 19 Gepants - p. 295 20. Chapter 20 Antidepressants, Antihypertensives & others - p. 307 21. Chapter 21 Anti-seizure medications for the management of migraine - p. 319 22. Chapter 22 OnabotulinumtoxinA - p. 331 23. Chapter 23 Gepants (for prevention) - p. 349 24. Chapter 24 (CGRP) Monocloncal antibodies - p. 363 25. Chapter 25 Oral drug delivery in migraine - p. 397 26. Chapter 26 Nasal and orally inhaled therapies for acute treatment of migraine - p. 409 27. Chapter 27 Subcutaneous/IM/transcutaneous (“injectables”) - p. 427 28. Chapter 28 Acute intravenous infusions for migraine - p. 435 29. Chapter 29 The role of digital platforms and smartphone apps - p. 453 30. Chapter 30 Herbal medicines - p. 477 31. Chapter 31 Phototherapy - p. 495 32. Chapter 32 Neuromodulation - p. 513 33. Chapter 33 Acupuncture (for episodic and chronic migraine) - p. 523 34. Chapter 34 Manual therapies - p. 537 35. Chapter 35 Nutraceuticals and diets - p. 555 36. Chapter 36 Mindfulness - p. 571 37. Chapter 37 Final perspectives - p. 591 38. Index - p. 597
Migraine Management: Current Pharmacological and Non-pharmacological Options is a comprehensive guide to established, recent, and ongoing pharmaceuticals and device development projects. The book provides detailed information on the historical developments of migraine pain management, druggable targets, drugs action mechanisms, drugs for acute treatment and preventive care of patients, administration routes, and alternative treatments. This is the ideal reference for academic researchers interested in anti-migraine pharmacology. It will also be a perfect reference for physicians and care professionals involved in the well-being of migraine patients.
1. Chapter 1 Introduction - p. 3 2. Chapter 2 Neuroanatomy and neurophysiology of migraine - p. 21 3. Chapter 3 Historical overview of migraine product development - p. 35 4. Chapter 4 Comorbidities in migraine - p. 61 5. Chapter 5 Not all migraine attacks are the same - p. 81 6. Chapter 6 Challenges and controversies; pharmacokinetics, linguistics, semantics and statistics - p. 93 7. Chapter 7 Calcitonin gene-related peptide (CGRP) and its role in migraine - p. 121 8. Chapter 8 PACAP - p. 139 9. Chapter 9 Src family kinases (SFKs) in migraine - p. 153 10. Chapter 10 Delta opioid receptor system - p. 167 11. Chapter 11 Piezo channels in peripheral trigeminal nociception - p. 177 12. Chapter 12 TRP channel antagonists - p. 189 13. Chapter 13 Simple analgesics and combination oral products - p. 211 14. Chapter 14 Medical cannabis and cannabinoids - p. 225 15. Chapter 15 Ergots - p. 243 16. Chapter 16 Triptans - p. 257 17. Chapter 17 Beta blocker (timolol) eye drops - p. 279 18. Chapter 18 Lasmiditan (and the ditan class) - p. 289 19. Chapter 19 Gepants - p. 295 20. Chapter 20 Antidepressants, Antihypertensives & others - p. 307 21. Chapter 21 Anti-seizure medications for the management of migraine - p. 319 22. Chapter 22 OnabotulinumtoxinA - p. 331 23. Chapter 23 Gepants (for prevention) - p. 349 24. Chapter 24 (CGRP) Monocloncal antibodies - p. 363 25. Chapter 25 Oral drug delivery in migraine - p. 397 26. Chapter 26 Nasal and orally inhaled therapies for acute treatment of migraine - p. 409 27. Chapter 27 Subcutaneous/IM/transcutaneous (“injectables”) - p. 427 28. Chapter 28 Acute intravenous infusions for migraine - p. 435 29. Chapter 29 The role of digital platforms and smartphone apps - p. 453 30. Chapter 30 Herbal medicines - p. 477 31. Chapter 31 Phototherapy - p. 495 32. Chapter 32 Neuromodulation - p. 513 33. Chapter 33 Acupuncture (for episodic and chronic migraine) - p. 523 34. Chapter 34 Manual therapies - p. 537 35. Chapter 35 Nutraceuticals and diets - p. 555 36. Chapter 36 Mindfulness - p. 571 37. Chapter 37 Final perspectives - p. 591 38. Index - p. 597
